XOMA Royalty Corporation Common Stock (XOMA) is a publicly traded Healthcare sector company. As of May 21, 2026, XOMA trades at $41.97 with a market cap of $522.21M and a P/E ratio of 25.40. XOMA moved +1.04% today. Year to date, XOMA is +57.70%; over the trailing twelve months it is +57.82%. Its 52-week range spans $18.35 to $42.81. Analyst consensus is neutral with an average price target of $42.67. Rallies surfaces XOMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Investors Challenge Proposed XOMA’s $39-Per-Share Deal with Ligand: XOMA Royalty Corporation agreed to be acquired by Ligand Pharmaceuticals for $39 per share, prompting an investigation into potential fiduciary breaches and terms that may limit competing bids. Shareholders are advised to evaluate their rights and may seek increased consideration or additional disclosures through litigation.
| Metric | Value |
|---|---|
| Price | $41.97 |
| Market Cap | $522.21M |
| P/E Ratio | 25.40 |
| EPS | $1.65 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.81 |
| 52-Week Low | $18.35 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $48.55M |
| Net Income | $33.81M |
| Gross Margin | 0.00% |
4 analysts cover XOMA: 0 strong buy, 1 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $42.67.